J&J Rebate Model for 340B Drug Discounts Draws Pushback
- August 30, 2024
Johnson & Johnson’s recently unveiled rebate-model policy for obtaining discounts on the company’s two drugs—Stelara and Xarelto—under the 340B program is coming under fire from the hospital industry and the government.
ARTICLE TAGS
You must be logged in to access this content.